Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 3/20 | 0.65 |
| ▸ | KDR | P35968 | 1/20 | 0.65 |
| ▸ | JAK3 | P52333 | 1/20 | 0.65 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.65 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | SRC | P12931 | 3/20 | 0.53 |
| ▸ | KIT | P10721 | 1/20 | 0.53 |
| ▸ | DHFR | P00374 | 2/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.47 |
| ▸ | PI4KA | P42356 | 1/20 | 0.47 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5494272 | 0.87 | LCK (0.58) | LCKKDRJAK3MAPK14BACE1 | |
| SCHEMBL5488838 | 0.86 | MAP4K4 (0.61) | LCKKDRJAK3MAPK14BACE1 | |
| SCHEMBL29515770 | 0.86 | DHFR (0.56) | LCKKDRJAK3MAPK14BACE1 | |
| SCHEMBL12575879 | 0.84 | LCK (0.55) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL3025007 | 0.84 | LCK (0.55) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL24335889 | 0.83 | PIK3CA (0.55) | LCKKDRJAK3MAPK14DHFR | |
| SCHEMBL12575968 | 0.83 | SRC (0.61) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL17803857 | 0.83 | LCK (0.62) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5496333 | 0.82 | LCK (0.59) | LCKKDRJAK3MAPK14SRC | |
| SCHEMBL5494720 | 0.82 | LCK (0.58) | LCKKDRJAK3MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1836174-B2 | ARYL NITROGEN-CONTAINING BICYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | AMGEN INC (US) | 2019-10-02 | — | — | EP | disclosed |
| CN-109843858-A | Certain chemical entities, composition and method | 润新生物公司 | 2019-06-04 | — | — | CN | disclosed |
| US-8389530-B2 | Substituted quinazoline compounds | FOVEA PHARMACEUTICALS (FR) | 2013-03-05 | — | — | US | disclosed |
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | FOVEA PHARMACEUTICALS SA | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004210-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS | MAP3K5, MAP3K1, MAP3K2 | LCK 392/4885KDR 296/4885JAK3 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.